文献速递肝病消化道肿瘤与早癌

甲状腺激素通过诱导分化与代谢重编程抑制肝细胞癌进展

Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming.
PubMed 文献 · J Hepatol · 2020-01-15

本研究在大鼠和小鼠肝癌模型中探究三碘甲状腺原氨酸(T3)对肝细胞癌(HCC)进展的影响。短期T3治疗使侵袭性癌前结节基因表达谱向正常肝脏转变,并减少HCC数量和负荷,停用后效果持续1个月;T3还抑制人HCC细胞系生长和致瘤能力。提示T3/TRβ轴再激活可诱导肿瘤细胞分化,T3或TRβ激动剂可能用于HCC治疗。

要点

  • T3短期治疗使癌前结节基因表达谱向正常肝脏转变,先于结节消失。
  • T3治疗显著减少HCC荷瘤大鼠的肿瘤数量和负荷,停用后效果持续1个月。
  • T3的抗肿瘤作用伴随Warburg代谢向氧化代谢转换及低分化标志物丢失。

核心结论

  • 再激活T3/TRβ轴可诱导肿瘤细胞向更良性表型分化,T3或其类似物尤其是TRβ激动剂可能成为HCC治疗工具。

研究设计与样本

  • 研究采用不同的大鼠和小鼠肝癌发生模型,并通过转录组分析、定量逆转录PCR、免疫组化和酶学测定评估T3对肿瘤发生及代谢/分化的影响。

主要发现

  • 短期T3治疗使最具侵袭性的癌前结节全局表达谱向正常肝脏转变,该基因组重编程先于结节消失。
  • T3治疗HCC荷瘤大鼠强烈减少HCC数量和负荷,伴随局部T3/TRβ轴再激活、Warburg代谢向氧化代谢转换及低分化肝细胞标志物丢失。
  • T3撤除1个月后效果仍持续,提示激素具有长久效应。
  • T3对人HCC细胞系生长和致瘤能力具有抑制活性。

临床怎么用

  • HCC常于晚期诊断而无法根治,甲状腺激素和/或甲状腺激素类似物可能对HCC患者治疗有用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Only limited therapeutic options are currently available for hepatocellular carcinoma (HCC), making the development of effective alternatives essential. Based on the recent finding that systemic or local hypothyroidism is associated with HCC development in humans and rodents, we investigated whether the thyroid hormone triiodothyronine (T3) could inhibit the progression of HCCs. METHODS: Different rat and mouse models of hepatocarcinogenesis were investigated. The effect of T3 on tumorigenesis and metabolism/differentiation was evaluated by transcriptomic analysis, quantitative reverse transcription PCR, immunohistochemistry, and enzymatic assay. RESULTS: A short treatment with T3 caused a shift in the global expression profile of the most aggressive preneoplastic nodules towards that of normal liver. This genomic reprogramming preceded the disappearance of nodules and involved reprogramming of metabolic genes, as well as pro-differentiating transcription factors, including Kruppel-like factor 9, a target of the thyroid hormone receptor β (TRβ). Treatment of HCC-bearing rats with T3 strongly reduced the number and burden of HCCs. Reactivation of a local T3/TRβ axis, a switch from Warburg to oxidative metabolism and loss of markers of poorly differentiated hepatocytes accompanied the reduced burden of HCC. This effect persisted 1 month after T3 withdrawal, suggesting a long-lasting effect of the hormone. The antitumorigenic effect of T3 was further supported by its inhibitory activity on cell growth and the tumorigenic ability of human HCC cell lines. CONCLUSIONS: Collectively, these findings suggest that reactivation of the T3/TRβ axis induces differentiation of neoplastic cells towards a more benign phenotype and that T3 or its analogs, particularly agonists of TRβ, could be useful tools in HCC therapy. LAY SUMMARY: Hepatocellular carcinoma (HCC) represents an important challenge for global health. Recent findings showed that systemic or local hypothyroidism is associated with HCC development. In rat models, we showed that administration of the thyroid hormone T3 impaired HCC progression, even when given at late stages. This is relevant from a translational point of view as HCC is often diagnosed at an advanced stage when it is no longer amenable to curative treatments. Thyroid hormones and/or thyromimetics could be useful for the treatment of patients with HCC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Kowalik MA, Puliga E, Cabras L, et al. Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming. J Hepatol. 2020. PMID: 31954205. doi:10.1016/j.jhep.2019.12.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。